Literature DB >> 19851803

Extrastriatal dopamine D(2) receptor occupancy in olanzapine-treated patients with schizophrenia.

Ryosuke Arakawa1, Hiroshi Ito, Masaki Okumura, Akihiro Takano, Hidehiko Takahashi, Harumasa Takano, Yoshiro Okubo, Tetsuya Suhara.   

Abstract

Olanzapine is described as a multi-acting receptor-targeted antipsychotic agent. Although regional differences of dopamine D(2) receptor occupancy, i.e., limbic selectivity, were reported for olanzapine, contradictory results were also reported. We measured dopamine D(2) receptor occupancy of olanzapine in extrastriatal regions in patients with schizophrenia using positron-emission tomography with [(11)C]FLB457 and the plasma concentrations of olanzapine. Ten patients with schizophrenia taking 5-20 mg/day of olanzapine participated. Dopamine D(2) receptor occupancy in the temporal cortex ranged from 61.1 to 85.8%, and plasma concentration was from 12.7 to 115.4 ng/ml. The ED(50) value was 3.4 mg/day for dose and 10.5 ng/ml for plasma concentration. The ED(50) values obtained in this study were quite similar to those previously reported in the striatum. In conclusion, although the subjects and methods were different from previous striatal occupancy studies, these results suggest that limbic occupancy by olanzapine may not be so different from that in the striatum.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19851803     DOI: 10.1007/s00406-009-0082-5

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  35 in total

1.  Extrastriatal dopamine D2 receptor density and affinity in the human brain measured by 3D PET.

Authors:  Tetsuya Suhara; Yasuhiko Sudo; Takashi Okauchi; Jun Maeda; Koichi Kawabe; Kazutoshi Suzuki; Yoshiro Okubo; Yoshifumi Nakashima; Hiroshi Ito; Shuji Tanada; Christer Halldin; Lars Farde
Journal:  Int J Neuropsychopharmacol       Date:  1999-06       Impact factor: 5.176

Review 2.  Olanzapine for schizophrenia.

Authors:  L Duggan; M Fenton; J Rathbone; R Dardennes; A El-Dosoky; S Indran
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

3.  Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol.

Authors:  Robert M Kessler; Mohammad Sib Ansari; Patrizia Riccardi; Rui Li; Karuna Jayathilake; Benoit Dawant; Herbert Y Meltzer
Journal:  Neuropsychopharmacology       Date:  2005-12       Impact factor: 7.853

4.  Limbic selectivity of clozapine.

Authors:  L S Pilowsky; R S Mulligan; P D Acton; P J Ell; D C Costa; R W Kerwin
Journal:  Lancet       Date:  1997-08-16       Impact factor: 79.321

5.  Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine.

Authors:  Robert M Kessler; M Sib Ansari; Patrizia Riccardi; Rui Li; Karuna Jayathilake; Benoit Dawant; Herbert Y Meltzer
Journal:  Neuropsychopharmacology       Date:  2006-05-31       Impact factor: 7.853

6.  Identification of extrastriatal dopamine D2 receptors in post mortem human brain with [125I]epidepride.

Authors:  R M Kessler; W O Whetsell; M S Ansari; J R Votaw; T de Paulis; J A Clanton; D E Schmidt; N S Mason; R G Manning
Journal:  Brain Res       Date:  1993-04-23       Impact factor: 3.252

7.  Striatal and extra-striatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo. [(123)I]-epidepride single photon emission tomography(SPET) study.

Authors:  C M Stephenson; V Bigliani; H M Jones; R S Mulligan; P D Acton; D Visvikis; P J Ell; R W Kerwin; L S Pilowsky
Journal:  Br J Psychiatry       Date:  2000-11       Impact factor: 9.319

8.  Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.

Authors:  L Farde; A L Nordström; F A Wiesel; S Pauli; C Halldin; G Sedvall
Journal:  Arch Gen Psychiatry       Date:  1992-07

9.  Effects of olanzapine on regional C-Fos expression in rat forebrain.

Authors:  G S Robertson; H C Fibiger
Journal:  Neuropsychopharmacology       Date:  1996-02       Impact factor: 7.853

10.  Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia.

Authors:  Ryosuke Arakawa; Hiroshi Ito; Akihiro Takano; Hidehiko Takahashi; Takuya Morimoto; Takeshi Sassa; Katsuya Ohta; Motoichiro Kato; Yoshiro Okubo; Tetsuya Suhara
Journal:  Psychopharmacology (Berl)       Date:  2007-12-06       Impact factor: 4.530

View more
  2 in total

1.  Striatal and extrastriatal dopamine D₂ receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [¹¹C]raclopride and [¹¹C]FLB457.

Authors:  Keisuke Takahata; Hiroshi Ito; Harumasa Takano; Ryosuke Arakawa; Hironobu Fujiwara; Yasuyuki Kimura; Fumitoshi Kodaka; Takeshi Sasaki; Tsuyoshi Nogami; Masayuki Suzuki; Tomohisa Nagashima; Hitoshi Shimada; Motoichiro Kato; Masaru Mimura; Tetsuya Suhara
Journal:  Psychopharmacology (Berl)       Date:  2012-01-12       Impact factor: 4.530

2.  Central nervous system drug evaluation using positron emission tomography.

Authors:  Mizuho Sekine; Jun Maeda; Hitoshi Shimada; Tsuyoshi Nogami; Ryosuke Arakawa; Harumasa Takano; Makoto Higuchi; Hiroshi Ito; Yoshiro Okubo; Tetsuya Suhara
Journal:  Clin Psychopharmacol Neurosci       Date:  2011-04-30       Impact factor: 2.582

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.